The Filing Desk

Iovance Biotherapeutics vs Keros Therapeutics

Iovance Biotherapeutics IOVA · Keros Therapeutics KROS · Biotechnology

Iovance Biotherapeutics reported revenue of $264 million in fiscal 2025, about the same as Keros Therapeutics' $244 million in fiscal 2025. Iovance Biotherapeutics had an operating margin of -153.1%, against 27.7% at Keros Therapeutics. Free cash flow was −$336 million at Iovance Biotherapeutics and $106 million at Keros Therapeutics.

Side by side

Iovance BiotherapeuticsKeros Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$264M$244M
Revenue growth60.6%—
Revenue growth a year, last 5 years——
Gross margin34.3%—
Operating margin−153.1%27.7%
Net margin−148.4%35.7%
Free cash flow−$336M$106M
Free cash flow margin−127.6%43.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$375M
Change in diluted share count23.3%1.1%
Last close$7.31$11.39
P/E at the last close——
Insider trades, last 12 months—bought $75,770, sold $506,996
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Iovance BiotherapeuticsKeros Therapeutics
Operating margin
Percent of revenue
Iovance BiotherapeuticsKeros Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Iovance BiotherapeuticsKeros Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Iovance Biotherapeutics and Keros Therapeutics pages.